Literature DB >> 22135634

Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda.

E Namukwaya1, F N Nakwagala, F Mulekya, H Mayanja-Kizza, R Mugerwa.   

Abstract

INTRODUCTION: Early identification of Tuberculosis (TB) treatment failure using cost effective means is urgently needed in developing nations. The study set out to describe affordable predictors of TB treatment failure in an African setting.
OBJECTIVE: To determine the predictors of treatment failure among patients with sputum smear positive pulmonary TB at Mulago hospital. The study was carried out in the TB clinic of Mulago hospital Kampala, Uganda. This was an unmatched case control study where fifty patients with a diagnosis of TB treatment failure (cases) and 100 patients declared cured after completing anti TB treatment (controls) were recruited into the study. Cases were compared with controls to determine predictors of treatment failure.
RESULTS: Significant predictors of treatment failure in this study included a positive sputum smear at 2 months of TB treatment (OR 20.63, 95%CI 5.42- 78.41) and poor adherence to anti TB treatment (OR 14.59, 95%CI 3.04-70.15).
CONCLUSION: This study identified a treatment related and a simple laboratory predictor of TB treatment failure in Mulago hospital which may be used in resource limited settings for early recognition of those at risk and early intervention.

Entities:  

Keywords:  Predictors; Pulmonary TB; Treatment failure

Mesh:

Substances:

Year:  2011        PMID: 22135634      PMCID: PMC3220128          DOI: 10.4314/ahs.v11i3.70079

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  17 in total

1.  Outcome of tuberculosis treatment in Hamburg: a survey, 1997-2001.

Authors:  R Diel; S Niemann
Journal:  Int J Tuberc Lung Dis       Date:  2003-02       Impact factor: 2.373

2.  How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.

Authors:  D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  1998-01       Impact factor: 2.373

3.  Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment.

Authors:  W J Burman; D L Cohn; C A Rietmeijer; F N Judson; J A Sbarbaro; R R Reves
Journal:  Chest       Date:  1997-05       Impact factor: 9.410

4.  Fever response of patients on therapy for pulmonary tuberculosis.

Authors:  S S Kiblawi; S J Jay; R B Stonehill; J Norton
Journal:  Am Rev Respir Dis       Date:  1981-01

5.  Risk factors for the development of non-response to first-line treatment for tuberculosis in southern Vietnam.

Authors:  V P Keane; N de Klerk; T Krieng; G Hammond; A W Musk
Journal:  Int J Epidemiol       Date:  1997-10       Impact factor: 7.196

6.  Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.

Authors:  J L Johnson; A Okwera; M J Vjecha; F Byekwaso; J Nakibali; S Nyole; J Milberg; T Aisu; C C Whalen; R D Mugerwa; J J Ellner
Journal:  Int J Tuberc Lung Dis       Date:  1997-10       Impact factor: 2.373

7.  Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.

Authors:  M C Becerra; J Freeman; J Bayona; S S Shin; J Y Kim; J J Furin; B Werner; A Sloutsky; R Timperi; M E Wilson; M Pagano; P E Farmer
Journal:  Int J Tuberc Lung Dis       Date:  2000-02       Impact factor: 2.373

8.  Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire.

Authors:  J H Perriëns; R L Colebunders; C Karahunga; J C Willame; J Jeugmans; M Kaboto; Y Mukadi; P Pauwels; R W Ryder; J Prignot
Journal:  Am Rev Respir Dis       Date:  1991-10

9.  Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

Authors:  A Jindani; A J Nunn; D A Enarson
Journal:  Lancet       Date:  2004 Oct 2-8       Impact factor: 79.321

10.  Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance.

Authors:  A Mahmoudi; M D Iseman
Journal:  JAMA       Date:  1993-07-07       Impact factor: 56.272

View more
  5 in total

1.  Predictors of delayed sputum smear conversion among pulmonary tuberculosis patients in Kota Kinabalu, Malaysia: A retrospective cohort study.

Authors:  Khalid Mokti; Zaleha Md Isa; Julaidah Sharip; Sahrol Nizam Abu Bakar; Azman Atil; Firdaus Hayati; Syed Sharizman Syed Abdul Rahim
Journal:  Medicine (Baltimore)       Date:  2021-08-06       Impact factor: 1.817

2.  Tuberculosis Chemotherapy Outcome in the Littoral Region of Cameroon: A Meta-analysis of Treatment Success Rate between 2014 and 2016.

Authors:  Dorgelesse F Kouemo Motse; Dickson Shey Nsagha; Dieudonné Adiogo; Loick P Kojom Foko; Pride M Teyim; Alain Chichom-Mefire; Jules C Nguedia Assob
Journal:  Biomed Res Int       Date:  2020-07-08       Impact factor: 3.411

3.  Factors associated with tuberculosis treatment failure in the Central East Health region of Burkina Faso.

Authors:  Adama Diallo; Désiré Lucien Dahourou; Ter Tiero Elias Dah; Souleymane Tassembedo; Romial Sawadogo; Nicolas Meda
Journal:  Pan Afr Med J       Date:  2018-08-28

4.  The burden of HIV on Tuberculosis patients in the Volta region of Ghana from 2012 to 2015: implication for Tuberculosis control.

Authors:  Eric Osei; Joyce Der; Richard Owusu; Philip Kofie; Wisdom Kudzo Axame
Journal:  BMC Infect Dis       Date:  2017-07-19       Impact factor: 3.090

5.  Treatment Outcomes of Tuberculosis at Asella Teaching Hospital, Ethiopia: Ten Years' Retrospective Aggregated Data.

Authors:  Ketema Tafess; Teresa Kisi Beyen; Adugna Abera; Geremew Tasew; Shimelis Mekit; Solomon Sisay; Legesse Tadesse; Gilman K H Siu
Journal:  Front Med (Lausanne)       Date:  2018-02-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.